Precipice Design recently worked with specialist pharmaceutical company, Circassia, to reimagine the NIOX VERO, a 'gold standard' point-of-care medical device which detects nitric oxide levels, a marker of airway inflammation, in patients' breath, to help diagnose and manage asthma.
Circassia challenged Precipice Design to further develop the established and class-leading NIOX VERO with the aim of offering additional choices to patients and clinicians who are seeking enhancements to the current device which will build on already superior patient usability and clinician efficiency.
"As a pioneering device in its field of respiratory medicine, the current NIOX VERO model is widely valued by medical professionals as the gold standard in FeNo testing," commented Miles Hawley, CEO at Precipice Design. "Our task was to further enhance the clinical and patient experience, by providing enhanced product and UI features."
Precipice Design worked closely with Circassia's in-house R&D team transforming the existing device to become the NIOX VERO Plus. The updated product has a new carry handle feature and reworked access to the breathing handle. In addition, the screen is larger, and the UI adapted, offering an enhanced user-friendly experience.
"During research conducted by our team across Europe, the US and China we iteratively stress-tested all physical and digital aspects of the new NIOX VERO Plus design, enhancing the original device and reimagining the UI," Hawley continued. "Its virtually wordless design and new 'dashboard' led visual aesthetic has been developed to be used across Circassia's key global markets. Patients and clinicians can choose between universal graphics, such as a balloon, accelerator style gauge or a floating feather, to guide their breathing into the device, further improving patient's and clinician's user experience, demonstrating the impactful new design undertaken by the consultancy."
